doi: 10.1021/acsnano.4c11278
A personalized treatment plan considers: medical history current medications injury type treatment goals overall health factors Proper guidance helps support safe and appropriate use
Tone your body in 30 minutes
Ca 2+ signaling from different organelles has a dual impact on ferroptosis sensitivity, highlighting the need for timely signal monitoring
Disclosures: Khushboo Agrawal: Nothing to Disclose, Archana Rastogi: Nothing to Disclose, Vipin Yadav: Nothing to Disclose, Gayatri Ramakrishna: Nothing to Disclose, SHIV SARIN: Nothing to Disclose 737 EFFECTS OF TIMELY TREATMENT ON OUTCOMES OF LARSUCOSTEROL FOR SEVERE ALCOHOL-ASSOCIATED HEPATITIS (AHFIRM TRIAL) Lance Stein 1 Mitchell Shiffman 2 Aparna Goel 3 Allison Kwong 3 Ashwini Mehta 4 Christophe Moreno 5 Alexandre LOUVET 6 Steven Flamm 7 Sanjaya Satapathy 8 Alexander Kuo 9 Daniel Ganger 10 Costica Aloman 11 Amanda Nicoll 12 Simone Strasser 13 Mack Mitchell 14 Srinivasan Dasarathy 15 Edmund Tse 16 Mark Thursz 17 Craig McClain 18 William Krebs 19 Deborah Scott 19 Christina Blevins 19 Julie Fergus 19 Norman Sussman 19 WeiQi Lin 19 Jim Brown 19 , 1 Piedmont Hospital Transplant Services, 2 Bon Secours Liver Institute, 3 Stanford University Medical Center, 4 The Liver Institute at Methodist, Dallas, 5 Universit Libre de Bruxelles, 6 University Hospital, Lille, 7 Rush University Medical Center, 8 Northwell Health, 9 Cedars-Sinai Medical Center, 10 Northwestern Memorial Hospital, 11 Westchase Medical Center, 12 Eastern Health, Melbourne, 13 Royal Prince Alfred Hospital, University of Sydney, 14 University of Texas Southwestern Medical Center, 15 Cleveland Clinic, 16 Royal Adelaide Hospital, 17 Imperial College London, 18 University of Louisville, 19 Durect Background: Previously, we reported findings in the Phase 2b AHFIRM trial evaluating efficacy of larsucosterol in patients with severe alcohol-associated hepatitis (sAH)
Identification of an apical Cl /HCO 3 exchanger in the small intestine
